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1. Introduction
Diabetes is a growing health problem worldwide in [1]. In a prospective study the risk of
cardiovascular death in patients with diabetes, without previous coronary heart disease (CHD)
is equal to that of patients with CHD without diabetes, with a higher risk factor in women in
[2]. This excessive risk is not explained by classic risk factors for cardiovascular disease such
as smoking, LDL-cholesterol, hypertension in [3]. This has led to a search for early markers of
vascular dysfunction (arterial stiffness) in diabetic patients that may pre-date the development
of overt clinical disease, offer a target for early intervention and delay the progress of cardio‐
vascular disease complications. Arterial walls stiffen with age. Once, the aging-associated
changes in arterial structural and functional changes were thought to be part of natural aging,
but this concept changed when data emerged showing that these changes are accelerated with
coexistent cardiovascular disease. For example, patients with diabetes exhibit increased
stiffness even after adjusting for age in [4] and this ‘accelerated’ arterial aging is well confirmed
to be a risk. Several non-invasive methods are currently used to assess vascular stiffness. An
extensive theoretical review of models underlying the definitions and assessment methods of
arterial stiffness estimates have been recently published in [5].
Pulse wave velocity is a recognized marker of large artery stiffness. Increased arterial stiffness
may be an important pathway linking diabetes to increased cardiovascular risk in [6]. Indeed,
increased arterial stiffness predicts the development of cardiovascular disease and mortality
in several groups of patients in [7] and has been shown to be elevated and predict premature
mortality in patients with type 2 diabetes (T2DM) in [8]. Abnormalities in rigidity markers
have been reported in patients with T2DM in [9,10] although not in all the arteries in [11], and
also without T2DM though predisposed to diabetes suggesting that genetic influences operate
through a mechanism different from structural alterations where body mass index (BMI), and
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glucose metabolism may be involved in [12,13,14]. Diabetic patients are subject to a myriad of
abnormalities (poor glycaemic control, dyslipidaemia etc) and it is difficult to determine which
abnormality accounts for arterial stiffening in [15]. We present the results of an analysis that
examined the independent association of PWV c-f with cardiovascular risk factors. This may
be useful to interpret its variations and is of clinical relevance, as arterial stiffening is an
independent predictor of an increase in cardiovascular risk in [16]. For this reason we used
PubMed for bibliographic research from 1990 to 2012 using the key words : diabetes non-
insulin dependent, T2DM, “PWVc-f,” “aortic pulse wave velocity,” and “aortic stiffness,”
which were combined with the terms determining and predictive. Articles with multiple
regression analysis were included to evaluate factors independently associated with PWV c-f
without any restriction on sample size or type. Variables not included in the regression analysis
model were considered not independently associated with PWV c-f. Pathogenetic mecha‐
nisms, pathophysiological implications and strategies to reduce arterial stiffening will be
discussed.
2. Pulse wave velocity carotid-femoral measurement
Pulse wave velocity carotid-femoral (PWVc-f) is currently considered the “gold standard” in
[5] of aortic distensibility, a biophysical property of the arterial wall that allows the pressure
waves generated by the left ventricle (buffering function) to be absorbed. PWVc-f, the velocity
of arterial wave propagation between two arterial sites, can be measured non-invasively, is
simple to determine, precise and reproducible in [17,18]. PWVc-f is calculated by dividing the
distance between the carotid and the femoral artery by the time delay of the arterial pulse
between these two arterial sites. The speed at which the pulse wave travels through an arterial
segment increases with increasing stiffness in [19].
3. Factors associated with Pulse wave velocity carotid-femoral
Age is a powerful determinant of PWVc.f in [20,21]. The results of this review confirm that this
is also the case for patients with T2DM. In particular, age is the main determinant of PWV c-f
in the multiple regression analysis in 89% of nineteen studies (Table 1). Age exposes the aortic
wall to degenerative phenomena such as collagen accumulation, fragmentation of elastic fibers
and calcification of the media responsible for the increase in aortic rigidity in [22,23,24]. This
interpretation gives a possible explanation of the relationship with arterial blood pressure that
is another major determinant of PWVc-f in 95% of the included studies. Longstanding arterial
pulsation in the central artery has a direct effect on the structural matrix proteins, collagen and
elastin in the arterial wall, disrupting muscular attachments and causing elastin fibers to
fatigue and fracture in [25]. This would explain why age and blood pressure are major
determinants of PWV c-f in [26]. It should be stressed that aortic stiffening is not only a
consequence of hypertension but is also in itself a pathogenetic mechanism of the disease.
Several studies report an independent association between heart rate (HR) and PWVc-f. The
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underlying mechanism is unknown, however several observations indicate that the rate of
elastin fatigue fracture depends on the number of stress cycles that is, the number of heartbeats
experienced which may explain the relationship between HR and PWVc-f in [27,28]. The
relationship between HR and PWV c-f suggests that HR may be a confounding factor that
should be incorporated into any analysis relating to PWVc-f. T2DM was associated with an
increase in PWVc-f in some studies in [29,30,31,32,33] but not in others in [34,35,36,37]. One
explanation for the variable association of PWVcf with diabetes mellitus is that it is gender
dependent, with a stronger association in women than in men in [38]. A relation between
duration of diabetes and PWV c-f has also been described in [39,40] although other authors
have failed to show this in [41]. Glycaemia and glycate hemoglobin (HbA1c) were associated
with an increase in PWV c-f in [42] that persisted in the multivariate analysis. In the study by
Smith et al [43] there was a weak association between PWV c-f and fasting plasma glucose that
persisted in the multivariate analysis. PWV c-f was unrelated to elements of the metabolic
syndrome (waist circumference, BMI, and triglycerides) and smoking. Only in [44] BMI was
associated to PWVc-f and waist-hip ratio in Strain et al [45]. More importantly, fasting glucose
concentration, 2 h post-challenge glucose and homeostasis model assessment for insulin
resistance (HOMA-IR) were independently related to PWV c-f after adjustment for age,
gender, mean arterial pressure, HR, BMI, renal function and antihypertensive medication in
[46]. Implying hyperglycaemic excursion and insulin resistance play important roles in the
pathogenesis of atherosclerosis. Possible contributors to increased arterial stiffening in T2DM
include impaired glycaemic control and the formation of advanced glycation. The aforemen‐
tioned are end products which lead to structural changes in the vessel walls. Kimoto et al 2006
showed that gender is a determinant of PWV c-f. In the study by Smith et al women have
greater age-related aorta stiffening than men, a finding consistent with the enhanced vascular
risk in women with diabetes. In the study by Taniwaki et al aortic stiffness while increased in
females, was not a risk factor of PWV c-f in the multiple regression analysis. None of the
selected studies report smoking as a determining factor in patients with T2DM. Dyslipidaemia
did not play an important role in atherosclerosis therefore it is plausible that hyperlipidaemia
and foam-cell-driven plaque formation may affect vascular wall integrity at a later stage in the
pathogenic process in [47]. Increased aortic stiffness was associated with retinopathy and
peripheral neuropathy after adjusting for possible confounding variables. Other variables
associated with increased aortic stiffness were old age, HR, diabetes duration, 24 h pulse
pressure, dyslipidaemia and physical inactivity in [48].
4. Coefficient of determination (R²) values
Thirteen studies (68%) reported R² values, representing the amount of variability in PWVc-f.
Furthermore, regression models could predict a part of the variability of PWVc-f (22–73% )
indicating that other factors (e.g. insulin resistance, advanced glycation end-products, genetic
factors) may play a more important role in arterial stiffness in T2DM.
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5. Pathogenetic mechanism of arterial stiffening
Arterial stiffness depends on the structure and function of the vessel wall. Alterations in the
extracellular matrix of the media and adventitia have long been implicated in the pathogenesis
of age and blood pressure-related increase in arterial stiffness in [49,50]. Data suggest that such
alterations may be caused not only by short-term hyperglycemia, but also by carbonyl and
oxidative stress and endothelial dysfunction in [51,52]. Impaired glucose tolerance also
enhances nonenzymatic glycation of proteins with covalent cross-linking of collagen (AGEs)
and alters the mechanical properties of interstitial tissue of the arterial wall in [53,54]. Chronic
hyperglycemia and hyperinsulinemia increases the local activity of renin-angiotensin-
aldosterone system (RAAS) and expression of angiotensin type I receptor in vascular tissue in
[55] promoting development of wall hypertrophy and fibrosis in [56,57]. In recent years there
has been growing evidence of the important role played by inflammation which can influence,
by different mechanisms, the increase in arterial stiffness (endothelial dysfunction, smooth
muscle proliferation and activation, changes in composition of extracellular matrix) in [58].
6. Pathophysiological implications
The principal function of the arterial system is to deliver an adequate supply of blood to tissues
and organs. In performing this primary conduit function, the arteries transform the pulsatile
flow generated by ventricular contraction into a continuous flow of blood in the periphery.
This latter cushioning function is dependent on the mechanical properties of the arterial walls.
Increased aortic stiffness has several detrimental effects on cardiovascular performance. A less
distensible aorta cannot efficiently accommodate the blood volume ejected by the left ventricle,
which results in high systolic pressure. In addition, diastolic pressure is decreased and pulse
pressure (PP) is thus increased. These haemodynamic modification influence ventricular
afterload and impair coronary perfusion in [59]. Indeed, PP is more closely predictive of
mortality in individuals with T2DM than systolic (SBP) and diastolic blood pressure (DBP) in
[60]. PWVc-f seems closely related to PP. Excessive pressure pulsatility enhances regional
stress and flow abnormalities in the central aorta and proximal large arteries and may
contribute to the propensity for focally severe atherosclerosis in these regions. Thus, excessive
aortic stiffness and increased pressure pulsatility contribute to damage the arterial wall and
may represent both a cause and a consequence of atherogenesis in [61]. Increased local pulsatile
pressure and strain increase the likelihood of plaque rupture and thereby contribute to the
increased risk of overt clinical events in individuals with atherosclerotic disease. In addition,
high pulsatility may be transferred down to arterioles, resulting in disruption of microcircu‐
lation leading to stroke, dementia, and to renal failure in [62,63]. A positive relationship
between PP and proteinuria has been observed in [64,65]. Such microvascular disease is
accentuated in patients with T2DM.
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7. Strategies to reduce arterial stiffening in type 2 diabetes
In patients at high risk of developing CVD, such as diabetic patients, it is important to improve
arterial stiffness. There are many studies reporting changes in arterial stiffness after various
interventions, either non-pharmacological or pharmacological. Non-pharmacological treat‐
ment able to reduce arterial stiffness include exercise training, weight loss, and various dietary
modifications, including low-salt diet, moderate alcohol consumption, α-linoleic acid, dark
chocolate, and fish oil in [66]. It is still debated whether the reduction in arterial stiffness after
antihypertensive treatment is only attributable to blood pressure (BP) lowering, or if additional
BP-independent effects are involved. However, renin–angiotensin–aldosterone system
(RAAS) inhibitors, such as ACE inhibitors and angiotensin II receptor blockers (ARBs), have
been widely suggested to have a BP-independent effect on arterial stiffness in [66,68]. Cur‐
rently, ARBs are recommended as first-line drugs for hypertension treatment in T2DM
patients. Several studies have reported that angiotensin receptor blockers (ARBs) also reduce
arterial stiffness in patients with hypertension and T2DM in [69,70]. Fish oil ingestion im‐
proved vascular compliance in patients with T2DM by increasing nitric oxide (NO) production
or release in [71]. Aerobic exercise has been reported to restore the loss of central arterial
compliance and would likely improve arterial stiffening in patients with T2DM in [72]. A
combined nutrition and walking program in [73] as well as a pure walking intervention in [74]
have also demonstrated prospectively a decrease in arterial stiffness in the middle-aged
diabetic population. In T2DM, 3 months of pioglitazone treatment reduced PWVc-f while
increasing adiponectin in [75] and lowering C-reactive protein. Interestingly, the decrease of
PWVc-f and C-reactive protein levels occurred irrespective of improved diabetic control,
suggesting that vascular and antidiabetic effects of glitazones may be partially independent.
Studies have shown reduction of arterial stiffness using compounds that affect or break the
structure of advanced glycation end-product crosslinks (AGEs) in [76].
8. Conclusions
Arteries stiffen with advancing age, even in the absence of clinically detectable atherosclerotic
disease. Diabetes has been shown to accelerate this age associated stiffening in [77] mainly
through nonenzymatic glycation, the reaction between glucose and the extracellular matrix
proteins in the arterial wall. Nonenzymatic glycation leads to the formation of increased
collagen crosslinks that result in increased arterial stiffness in [78]. The results of this review
show that in T2DM, the increase in aortic stiffness is independent from other common
atherosclerotic risk factors. The principal determinants of PWV c-f are age and arterial blood
pressure suggesting that an increase in aortic stiffness could be explained in terms of age and
blood pressure. This review has certain limits: First, the studies were cross-sectional, and could
not reveal causal relationships. Future studies should include prospective studies to elucidate
the contribution of environmental-genetic factors over time to arterial stiffening. Secondly,
only studies reporting PWV c-f as a measure of arterial stiffness were included. There is
considerable variability in agreement between measures of stiffness and PWVc-f is clinically
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References Sample (n°) Men% Age M
PWVc-f
m/s
R2
(%)
Variables 
associated
with PWVc-f
Other variables
Tanokuchi et al
 1995 34 107 T2DM 54 59 H 9,4 - Age, SBP,DBP -
Taniwaki et al 
1999 39
271 T2DM
285 C
44
51
51
50 U
9
7 33
Age-Diabetes 
duration -
Amar et al
 20014 247 T2DM,HC 52 54 C 8,8 34 Age.SBP,HR Apolipoprotein
Aoun et al 
200141
122 T2DM
122 Ccontrol
66
66
58
58 C
13
12 - Age,MBP -
Kimoto et al 
2003 30
161 T2DM,
129 Control
53
43
60
59 N
-
- 47 Age-SBP-T2DM -
Lacy et al 
2004 29
66 T2DM
66 Control
68
68 5555 S
9,3
7,7 73
Age. 
SBP,DBP,HR,T2DM
Previous history of 
cardiovascular disease
Tedesco et al
 2004 42
50 T2DM
85 T2DM -HT
60
39
53
55 C
11
13,8 22 MBP FPG
Silva et al
 2004 37 102 T2DM 37 55 C 12,6 - Age.24-h SBP -
Smith et al
 2005 43 134 T2DM 66 61 S 10,2 55
Age,,PP, Diabetes 
duration HT drugs, ACEI/ARB use
Paini et al 
2006 44 126 T2DM 58 63 C 18,3 33 Age,SBP, BMI
Kimoto et al 
2006 31
434 T2DM with and
without CKD 56 6259 H 12,5 55 Age,SBP, T2DM,
Sex male, GFR,
non cholesterol HDL
Strain et al 
2006 45
51 European T2DM
66 African
Caribbean T2DM
49
36
57
57
C
C
14
15 -
Age,SBP,MBP,HR
Age,MBP Waist:hip ratio
Lee et al 
2007 33
18 T2DM
20 Control
66
63 MR
8,8
6,2 70 Age,SBP,T2DM -
Matsumae et al 
2008 40
94 Hemodialysis
with T2DM
148 Hemodialysis
without T2DM
59 65 H 11 32
SBP, Diabetes 
duration
Age,SBP,HR,
HbA1c
Duration HD, HbA1c
Saez et al 
2008 32
318 Renal transplant
with and
without T2DM 49 52 S 9 - Age,SBP,T2DM -
Rahman et al 
2008 36
T2DM 30
IGT 30
NG 30
47
47
47
S
10,4
9,5
8,7
29 Age,SBP 2hPPG
Cardoso et al 
2009 48
482 T2DM
334
148
38
37 5967 C
<12
>12 -
Age,24-
hPP,HR,Diabetes 
duration
Dyslipidemia,retinopathy,
physical inactivity, 
peripheral neuropathy
Webb et al 
2010 46
176 NGM
219 IGR
175 T2DM
58
59
59
55
53
57
U
8,9
9,7
10
51
Age, MBP,HR Sex 
Female FPG,2HPG,HOMA-IR
Naka et al 
2012 35 165 T2DM 30 66 S 10,2 25 Age, SBP -
Table 1. Characteristic of studies on PWVc-f included in the review
Type 2 Diabetes148
the most relevant. PWV c-f is easy to measure with specifically designed devices. High aortic
stiffness doubles the risk of cardiovascular events or mortality compared to low aortic stiffness,
and the predictive value of high PWV c-f is greater in high-risk patients, such as patients with
T2DM. PWVc-f expresses the cumulative effect of various factors on the arterial system and
their interplay with genetic predisposition. In contrast to cardiovascular risk factors, such as
blood pressure or cholesterol, that may fluctuate over time, PWVc-f is relatively stable, since
it is mostly influenced by alterations of arterial wall structure. The 2007 European Society of
Hypertension & European Society of Cardiology guidelines for the management of hyperten‐
sion rightfully included increased PWVc-f as subclinical target-organ damage, and recom‐
mended aggressive management of patients with high PWVc-f in [79]. The World Health
Organization estimates that by the year 2025 more than 300 million people worldwide will
have diabetes [80]. Measurement of aortic PWV c-f should be integrated in the examination
and risk stratification of patients with T2DM.
M, method, C, compilor; S, SphygmoCor; U, ultrasound; H, Hasegawa method MR, magnetic
resonance, N, indicates noninvasivepressure recordings. R2,coefficient of determination, SBP,
systolic blood pressure, DBP, diastolic blood pressure, PP, pulse pressure, MBP, mean blood
pressure, HR, heart rate, FPG, fasting plasma glucose, T2DM, type 2 diabetes; BMI, body mass
index, ACE angiotensin-converting enzyme ARB, angiotensin receptor blocker, GFR glomer‐
ular filtration rate, HbA1c, glycate hemoglobin, 2HPG, 2 h post-challenge glucose HOMA-IR,
homeostasis model assessment for insulin resistance, IGT impaired glucose tolerance IR
insulin resistance, IGR, impaired glucose regulation, HT, hypertensive HC, hypercholestero‐
lemia.
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